Late-onset grade 4 neutropenia occurred in 3 (5.6%) of 54 non-Hodgkin's lymphoma patients treated with rituximab between September 2001 and March 2004. Neutropenia appeared 5 to 25 weeks after administration of cytotoxic agents in combination with rituximab and recurred 4 and 17 weeks after the first onset in 2 patients. Five episodes occurred in a total of 332 cycles of rituximab therapy. Bone marrow findings at the time of late-onset neutropenia showed neutrophil maturation arrest with or without reversible myeloid dysplasia in 3 episodes and selective depletion of the myeloid series in 1 episode. Neither circulating immune complexes nor antineutrophil antibodies were detected during the 3 episodes that we evaluated. Bone marrow cells stained CD8- and CD57-. Late-onset neutropenia resolved 5 to 7 days after granulocyte colony-stimulating factor therapy was started. Further studies are needed to determine how rituximab functions and to identify appropriate countermeasures.

Download full-text PDF

Source
http://dx.doi.org/10.1532/IJH97.05105DOI Listing

Publication Analysis

Top Keywords

late-onset neutropenia
12
patients treated
8
treated rituximab
8
non-hodgkin's lymphoma
8
bone marrow
8
rituximab
5
late-onset
4
neutropenia patients
4
rituximab non-hodgkin's
4
lymphoma late-onset
4

Similar Publications

Neonatal Late-Onset Sepsis Due to Acinetobacter baumannii: A Case Report.

Cureus

November 2024

Neonatology Department, Maternidade Daniel de Matos, Unidade Local de Saúde de Coimbra, Coimbra, PRT.

Late-onset sepsis (LOS) is commonly associated with pathogens acquired in hospital or community settings and carries a significant risk of morbidity and mortality in neonates. We present a case of a late preterm neonate, born at 36 weeks and 2 days with low birth weight (1700 g), who was admitted to the neonatal intensive care unit (NICU) and developed LOS on the fourth day of life. LOS was diagnosed in the context of fever and lethargy, mild thrombocytopenia, leukopenia, and lymphopenia, and was caused by multidrug-resistant (MDR) , confirmed through blood culture.

View Article and Find Full Text PDF

Immune effector cell-associated neurotoxicity syndrome usually occurs within the first four weeks of chimeric antigen receptor (CAR)-T cell therapy. In addition, prolonged cytopenia is a long-term adverse effect following the use of CAR T-cell therapies. Here, we present a case of prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis.

View Article and Find Full Text PDF

Background: Spondyloenchondrodysplasia is classified as an interferonopathy resulting from recessive mutations in the gene and manifests with various clinical features, including distinctive skeletal dysplasia, neurological abnormalities, immune dysfunction resembling systemic lupus erythematosus (SLE) and Sjogren's syndrome. While SLE is typically considered multifactorial and more prevalent in adulthood, a subset of approximately 10%-25% of childhood cases arise from monogenic form. Among these, spondyloenchondrodysplasia accounts for only a rare fraction of monogenic lupus cases, with only 22 reported instances in the literature.

View Article and Find Full Text PDF

Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis.

Med

November 2024

Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. Electronic address:

Background: As B cell-depleting therapies in multiple sclerosis (MS) have gained significant importance in the last several years, their long-term safety profile is of considerable clinical interest. Late-onset neutropenia (LON) is a rare, but potentially severe, adverse event that was first described in patients with rheumatic disorders under therapy with rituximab. Ofatumumab was approved in 2021 for the treatment of relapsing-remitting multiple sclerosis (RRMS).

View Article and Find Full Text PDF

Blood-dominant disease in late-and-early-onset lupus: A systematic review and meta-analysis.

Autoimmun Rev

November 2024

Division of Rheumatology, University Hospitals/Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH, 44106, USA.. Electronic address:

Article Synopsis
  • - This study aims to compare the hematological manifestations between early-onset systemic lupus erythematosus (erSLE) patients (aged ≤50) and late-onset patients (ltSLE) (aged >50) through a meta-analysis of previous research.
  • - Results from 39 studies involving over 19,000 patients show that erSLE patients exhibit higher frequencies of autoimmune hemolytic anemia, lymphopenia, leukopenia, and lymphadenopathy compared to ltSLE patients, while the rates of thrombosis and thrombocytopenia were similar in both groups.
  • - The findings suggest that it may be challenging to link certain hematological issues to SLE in older patients due to other
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!